172936-99-1 Usage
Molecular structure
2-[6(S)-[3-(Diphenylmethyl)-6-oxo-1,6-dihydropyridazin-1-ylmethyl]-5,6,7,8-tetrahydro-1-naphthyloxy]acetic acid has a complex molecular structure containing a naphthyl group, a dihydropyridazinylmethyl group, and an acetic acid group.
Potential pharmaceutical properties
This chemical compound has potential pharmaceutical properties, making it a candidate for further research and development in the pharmaceutical industry.
Therapeutic applications
Although further research is needed, the compound may have potential therapeutic applications due to its unique molecular structure and properties.
Biological activity
The precise biological activity of this compound is not yet fully understood, but it may affect various physiological processes, making it a subject of interest for pharmaceutical development.
Naphthyl group
The presence of a naphthyl group in the compound contributes to its potential pharmaceutical properties and may be involved in its therapeutic applications.
Dihydropyridazinylmethyl group
This group is part of the compound's structure and may play a role in its potential therapeutic applications and biological activity.
Acetic acid group
The acetic acid group is another component of the compound's structure, which may contribute to its potential pharmaceutical properties and therapeutic applications.
Further research needed
The compound's uses and effects are not fully characterized, and additional research is required to understand its full potential in pharmaceutical development.
Check Digit Verification of cas no
The CAS Registry Mumber 172936-99-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,2,9,3 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 172936-99:
(8*1)+(7*7)+(6*2)+(5*9)+(4*3)+(3*6)+(2*9)+(1*9)=171
171 % 10 = 1
So 172936-99-1 is a valid CAS Registry Number.
172936-99-1Relevant articles and documents
A novel pyridazinone derivative as a nonprostanoid PGI2 agonist
Tsubaki, Kazunori,Taniguchi, Kiyoshi,Tabuchi, Seiichiro,Okitsu, Osamu,Hattori, Kouji,Seki, Jiro,Sakane, Kazuo,Tanaka, Hirokazu
, p. 2787 - 2790 (2007/10/03)
A novel optically pure pyridazinone derivative was synthesized and identified as a nonprostanoid PGI2 agonist. It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 μM and has high oral bioavailability (
